ArticleJournal of ovarian research2025

Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis.

Kun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.